Wings Therapeutics Competitors and Similar CompaniesClear all
Wings Therapeutics's competitors and similar companies include Bluebird Bio, ZoBio, Neuron23 and Sarepta Therapeutics.
 Wings Therapeutics Wings Therapeutics is a biotechnology company engaged in the development of therapies for patients suffering from Dystrophic Epidermolysis Bullosa (DEB), a rare genetic skin blistering disease. |  ZoBio ZoBio is a company that provides gene to structure research services in early stage drug discovery. |  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | |||
Founding Date | Founding Date 2019 | Founding Date 1992 | Founding Date 2004 | Founding Date 2018 | Founding Date 1980 |
Type | Type Private | Type Public | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations Berkeley, US HQ | Locations Somerville, US HQ | Locations Leiden, NL HQ | Locations South San Francisco, US HQ | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US |
Employees | Employees 5 | Employees 32338% decrease | Employees 432% decrease | Employees 427% decrease | Employees 1,31413% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 95.4 m | Valuation ($) N/A | Valuation ($) 507.1 m | Valuation ($) 12.4 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $83.8m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $2.2b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $89.4m (FY, 2024) | Cost of goods N/A | Cost of goods N/A | Cost of goods $25.5m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit ($5.6m) (FY, 2024) | Gross profit N/A | Gross profit N/A | Gross profit $2.2b (FY, 2025) |
Net income | Net income N/A | Net income ($240.7m) (FY, 2024) | Net income N/A | Net income N/A | Net income ($713.4m) (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round $ 1.5m (almost 7 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 80m (over 5 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 1.5m | Total funding raised $ 409m | Total funding raised N/A | Total funding raised $ 113.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Bluebird Bio
HQ
Somerville, US
Employees
323↓ 38% decrease
Bluebird Bio is a developer of gene therapies for severe genetic diseases.
View companyZoBio
HQ
Leiden, NL
Employees
43↓ 2% decrease
ZoBio is a company that provides gene to structure research services in early stage drug discovery.
View company
Neuron23
HQ
South San Francisco, US
Employees
42↓ 7% decrease
Neuron23 is a biotechnology company that develops medicines for genetic disorders.
View companySarepta Therapeutics
HQ
Cambridge, US
Employees
1,314↑ 13% increase
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
View company